Raymond James & Associates Logic Bio Therapeutics, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 11, 2021
SELL
$4.03 - $7.57 $42,210 - $79,288
-10,474 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$6.8 - $9.16 $71,223 - $95,941
10,474 New
10,474 $76,000

About LogicBio Therapeutics, Inc.

LOGC Quotes by TradingView
  • Ticker LOGC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,962,700
  • Description
  • LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...
More about LOGC
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email